Hep C trial for Biotron
Thursday, 07 August, 2008
Biotron [ASX: BIT] has started Phase Ib/IIa clinical trials of its BIT225 hepatitis C candidate.
The study will enlist 18 hep C positive patients, who will be sorted into two dosage groups and a placebo control group.
The trial is primarily a safety and tolerability study, but determining the pharmacokinetics and effectiveness of the drug are secondary objectives of the trial.
Biotron expects to conclude the trial by the end of the year.
BIT225 targets the p7 protein of HCV, and has demonstrated good antiviral activity in surrogate models of HCV infection. This trial follows on from a successful Phase I trail conducted in healthy volunteers.
Biotron began as the commercialisation arm of the John Curtin School of Medical Research at ANU.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
